Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study

Autores de IIS La Fe

• Miguel Ángel Sanz Alonso

  Autor

• Pau Montesinos Fernández

  Autor

Participantes ajenos a IIS La Fe

• Ocio EM
• Herrera P
• Olave MT
• Castro N
• Pérez-Simón JA
• Brunet S
• Oriol A
• Mateo M
• López J
• Chillón MC
• Prieto-Conde MI
• Díez-Campelo M
• González M
• Vidriales MB
• Mateos MV
• San Miguel JF
• PETHEMA Group

Grupos

• Hematología y Hemoterapia

Abstract

This phase Ib/II trial combined the pan-deacetylase inhibitor panobinostat with chemotherapy followed by panobinostat maintenance in elderly patients with newly diagnosed acute myeloid leukemia. Patients with prior history of myelodysplastic syndrome were excluded and 38 evaluable patients were included in the study (median age: 71 years; range: 65-83). Study patients received an induction with idarubicin (8 mg/m(2) iv days 1-3) plus cytarabine (100 mg/m2 iv days 1-7) plus panobinostat po at escalating doses (days 8, 10, 12, 15, 17 and 19) that could be repeated in non-responding patients. Patients achieving complete remission received a consolidation cycle with the same schema, followed by panobinostat maintenance (40 mg po 3 days/week) every other week until progression. Thirty-one patients were treated at the maximum tolerated dose of panobinostat in the combination (10 mg) with good tolerability. Complete remission rate was 64% with a time to relapse of 17.0 months (12.8-21.1). Median overall survival for the whole series was 17 months (5.5-28.4). Moreover, in 4 of 5 patients with persistent minimal residual disease before maintenance, panobinostat monotherapy reduced its levels, with complete negativization in two of them. Maintenance phase was well tolerated. The most frequent adverse events were thrombocytopenia (25% grades 3/4), and gastrointestinal toxicity, asthenia and anorexia (mainly grades 1/2). Five patients required dose reduction during this phase, but only one discontinued therapy due to toxicity. These results suggest that panobinostat is one of the first novel agents with activity in elderly acute myeloid leukemia patients, and suggest further investigation is warranted, particularly in the context of maintenance therapy.

Keywords

• MINIMAL RESIDUAL DISEASE; MYELODYSPLASTIC SYNDROMES; POSTREMISSION THERAPY; CELL TRANSPLANTATION; POOR-PROGNOSIS; OLDER-ADULTS; OPEN-LABEL; II TRIAL; VORINOSTAT; OUTCOMES